# Universal Health Realty Income Trust: overview UHT · NYSE · CIK 798783 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/uht.md) · [Financials](/companies/uht/financials.md) · [Filings](/companies/uht/filings.md) · [Insiders](/companies/uht/insiders.md) Latest reported revenue: [$25.0m](/filings/0001193125-26-340281.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-340281). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.5](/filings/0001193125-25-272382.md) | [24.6 d](/filings/0001193125-26-071594.md) | [24.5](/filings/0001193125-26-211984.md) | [24.9](/filings/0001193125-26-340281.md) | [25.3](/filings/0001193125-25-272382.md) | [24.5 d](/filings/0001193125-26-071594.md) | [24.5](/filings/0001193125-26-211984.md) | [25.0](/filings/0001193125-26-340281.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [34.7%](/filings/0001193125-25-272382.md) | [37.6% d](/filings/0001193125-26-071594.md) | [36.8%](/filings/0001193125-26-211984.md) | [35.6%](/filings/0001193125-26-340281.md) | [33.2%](/filings/0001193125-25-272382.md) | [34.7% d](/filings/0001193125-26-071594.md) | [36.5%](/filings/0001193125-26-211984.md) | [36.8%](/filings/0001193125-26-340281.md) | | Net margin | % | [16.3%](/filings/0001193125-25-272382.md) | [18.9% d](/filings/0001193125-26-071594.md) | [19.5%](/filings/0001193125-26-211984.md) | [18.1%](/filings/0001193125-26-340281.md) | [15.9%](/filings/0001193125-25-272382.md) | [17.7% d](/filings/0001193125-26-071594.md) | [20.5%](/filings/0001193125-26-211984.md) | [23.6%](/filings/0001193125-26-340281.md) | | Diluted EPS | $ per share | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.34](/filings/0001193125-26-211984.md) | [0.32](/filings/0001193125-26-340281.md) | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.36](/filings/0001193125-26-211984.md) | [0.43](/filings/0001193125-26-340281.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [84.2](/filings/0000950170-24-021191.md) | [90.6](/filings/0000950170-25-027861.md) | [95.6](/filings/0001193125-26-071594.md) | [99.0](/filings/0001193125-26-071594.md) | [99.2](/filings/0001193125-26-071594.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [34.3%](/filings/0000950170-24-021191.md) | [33.8%](/filings/0000950170-25-027861.md) | [32.8%](/filings/0001193125-26-071594.md) | [37.2%](/filings/0001193125-26-071594.md) | [35.0%](/filings/0001193125-26-071594.md) | | Net margin | % | [129.7%](/filings/0000950170-24-021191.md) | [23.3%](/filings/0000950170-25-027861.md) | [16.1%](/filings/0001193125-26-071594.md) | [19.4%](/filings/0001193125-26-071594.md) | [17.8%](/filings/0001193125-26-071594.md) | | Diluted EPS | $ per share | [7.92](/filings/0000950170-24-021191.md) | [1.53](/filings/0000950170-25-027861.md) | [1.11](/filings/0001193125-26-071594.md) | [1.39](/filings/0001193125-26-071594.md) | [1.27](/filings/0001193125-26-071594.md) | | Free cash flow | $m | [34.7](/filings/0000950170-24-021191.md) | [33.2](/filings/0000950170-25-027861.md) | [35.3](/filings/0001193125-26-071594.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/uht/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $65.4m | 1,492,098 | | Reduced −768,355 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $37.1m | 845,483 | | Reduced −112,303 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $24.6m | 560,954 | | Reduced −34,299 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $16.6m | 377,502 | | Reduced −181,758 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $16.5m | 375,669 | | Added +22,565 | | [MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.](/funds/1705339.md) | 2026-06-30 | $15.5m | 353,543 | | Added +13,413 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $11.7m | 267,488 | | Added +254,570 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $10.1m | 229,241 | | Added +100,606 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $9.1m | 206,730 | | Added +75,957 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $8.8m | 200,666 | | Added +127,275 | ## Recent filings [All 570 filings](/companies/uht/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 16:25 ET | [8-K](/filings/0001193125-26-434277.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-434277 | | 2026-08-07 | 16:15 ET | [10-Q](/filings/0001193125-26-340281.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340281 | | 2026-07-27 | 16:25 ET | [8-K](/filings/0001193125-26-318144.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-318144 | | 2026-06-11 | 16:15 ET | [8-K](/filings/0001193125-26-267569.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-267569 | | 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211984.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211984 | | 2026-04-28 | 06:30 ET | [DEF 14A](/filings/0001193125-26-183412.md) | Proxy statement, period 2026-06-10 | 0001193125-26-183412 | | 2026-04-27 | 16:25 ET | [8-K](/filings/0001193125-26-182162.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-182162 | | 2026-04-24 | 08:15 ET | [8-K](/filings/0001193125-26-175196.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-175196 | | 2026-02-25 | 16:25 ET | [8-K](/filings/0001193125-26-071714.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071714 | | 2026-02-25 | 16:16 ET | [10-K](/filings/0001193125-26-071594.md) | Annual report, period 2025-12-31 | 0001193125-26-071594 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071594.md), filed Feb 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/c7935ef9-83ff-439d-8126-10242e28e42a) ## About the filer - CIK: 798783 - Tickers: UHT - Exchange: NYSE - SIC code: 6798 Real Estate Investment Trusts - State of incorporation: MD - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:26 ET. No prices; not investment advice.